Last checked at 
LONDON (Alliance News) - Life science-focused debt investor BioPharma Credit PLC said on Monday it has become the lead investor and collateral agent for a USD315.0 million loan to an unnamed pharmaceutical products developer.
BioPharma Credit will provide USD194.0 million with co-investors providing USD121.0 million.
Key terms of the investment includes a five year final maturity and a high single-digit floating coupon. Funding is expected to close in the next 15 days.
Shares in BioPharma Credit were down 0.5% at USD1.03 on Monday.